Suppression of the lipid peroxidation process in the CNS reduces neurological expression of experimentally induced autoimmune encephalomyelitis

Folia Neuropathologica

Volumn 51, Issue 1, 2013, Pages 51-57

  Ljubisavljevic, Srdjan ^a   Stojanovic, Ivana ^a   Pavlovic, Dusica ^a   Milojkovic, Maja ^a   Sokolovic, Dusan ^a   Stevanovic, Ivana ^b   Petrovic, Aleksandar ^a  

^a UNIVERSITY OF NI   (Serbia)

^b UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

Aminoguanidine; EAE; Lipid peroxidation; Malondialdehyde; N acetyl cysteine

Indexed keywords

ACETYLCYSTEINE; AMINOGUANIDINE; MALONALDEHYDE; MYELIN BASIC PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBELLUM; CONTROLLED STUDY; FEMALE; LIPID PEROXIDATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; RAT; SPINAL CORD;

EID: 84876237888     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: 10.5114/fn.2013.34196     Document Type: Article

References (32)

1. Acar G. Nitric oxide as an activity marker in multiple sclerosis. J Neurol 2003; 250: 588-592.
2. Andreeva LI, Kozhemiakin LA, Kishkun AA. Modification of the method of determining lipid peroxidation in a test using thiobarbituric acid. Lab Delo 1988; 11: 41-43.
3. Bast A, Haenen GR, Doelman CJA. Oxidants and antioxidants: state of the art. Am J Med 1991; 91: 2S-13S.
4. Besler HT, Comoglu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 2003; 6: 189-196.
5. Bongarzone ER, Pasquini JM, Soto EF. Oxidative damage to proteins and lipids of CNS myelin produced by in vitro generated reactive oxygen species. J Neurosci Res 1995; 41; 213-221.
6. Calabrese V, Scapagnini G, Ravagna A, Bella R, Foresti R, Bates TE, Giuffrida Stella AM, Pennisi G. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and Snitrosothiols and with changes in glutathione levels. J Neurosci Res 2002; 70: 580-587.
7. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
8. Fukuda M, Kanou F, Shimada N, Sawabe M, Saito Y, Murayama S, Hashimoto M, Maruyama N, Ishigami A. Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's disease. Biomed Res 2009; 30: 227-233.
9. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004; 251: 261-268.
10. Gonsette RE. Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis? Mult Scler 2008; 14: 22-34.
11. Hunter MI, Nlemadim BC, Davidson DL. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluids from multiple sclerosis patients. Neurochem Res 1985; 10: 1645-1652.
12. Jana A, Pahan K. Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: implications for multiple sclerosis. J Neuroimmune Pharmacol 2007; 2: 184-193.
13. Kalyvas A, David S. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 2004; 41: 323-335.
14. Kronke M, Adam-Klages S. Role of caspases in TNF-mediated regulation of cPLA2. FEBS Lett 2002; 531: 18-22.
15. Ljubisavljevic S, Stojanovic I, Pavlovic D, Sokolovic D, Stevanovic I. Aminoguanidine and N-Acetyl-Cysteine supress oxidative and nitrosative stress in EAE rat brains. Redox Rep 2011; 16: 166-172.
16. Ljubisavljevic S, Stojanovic I, Pavlovic D, Milojkovic M, Vojinovic S, Sokolovic D, Stevanovic I. Correlation of nitric oxide levels in the cerebellum and spinal cord of experimental autoimmune encephalomyelitis rats with clinical symptoms. Acta Neurobiol Exp 2012; 72: 33-39.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
18. Marusic S, Leach MW, Pelker JW, Azoitei ML, Uozumi N, Cui J, Shen MW, DeClercq CM, Miyashiro JS, Carito BA, Thakker P, Simmons DL, Leonard JP, Shimizu T, Clark JD. Cytosolic phospholipase A2a-deficient mice are resistant to experimental autoimmune encephalomyelitis. J Exp Med 2005; 202: 841-851.
19. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 1993; 151: 2132-2141.
20. Miller E, Mrowicka M, Saluk-Juszczak J, Majsterek I. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem Res 2011; 36: 1012-1016.
21. Nadkarni DV, Sayre LM. Structural definition of early lysine and histidine adduction chemistry of 4-hydroxynonenal. Chem Res Toxicol 1995; 8: 284-291.
22. Naidoo R, Knapp ML. Studies of lipid peroxidation products in cerebral fluid and serum in multiple sclerosis and other conditions. Clin Chem 1992; 38: 2449-2454.
23. Ponomarev ED, Shriver LP, Maresz K, Dittel BN. Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 2005; 81: 374-389.
24. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991; 288: 481-487.
25. Sajad M, Zargan J, Chawla R, Umar S, Sadaqat M, Khan H. Hippocampal neurodegeneration in experimental autoimmune encephalomyelitis (EAE): potential role of inflammation activated myeloperoxidase. Mol Cell Biochem 2009; 328: 183-188.
26. Salemi G, Gueli MC, Vitale F et al. Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis 2010; 9: 19-21.
27. Smith KJ, Kapoor R, Felts PA. Demyelination: The Role of Reactive Oxygen and Nitrogen Species. Brain Pathol 1999; 9: 69-92.
28. Subczynski WK, Hyde JS. Concentration of oxygen in lipid bilayers using a spin-label method. Biophys J 1983; 41: 283-286.
29. Tiberio M, Chard DT, Altmann GR, Davies G, Griffin CM, McLean MA, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH. Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study. J Neurol 2006; 253: 224-230.
30. Wallberg M, Bergquist J, Achour A, Breij E, Harris RA. Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to increased immunogenicity and encephalitogenicity. Eur J Immunol 2007; 37: 1986-1995.
31. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HPN, Issa PC, Cano M, Brandstätter H, Tsimikas S, Skerka C, Superti-Furga G, Handa JT, Zipfel PF, Witztum JL, Christoph J. Binder Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011; 478: 76-81.
32. Wuttge DM, Bruzelius M, Stemme S. T-cell recognition of lipid peroxidation products breaks tolerance to self proteins. Immunology 1999; 98: 273-279.